JARID2 promotes prostate cancer progression via TET3-activated FAK/PI3K/AKT pathway

This study investigates the role of JARID2, a component of the Polycomb Repressive Complex 2, in prostate cancer progression. Using clinical data and functional assays, researchers found that JARID2 is overexpressed in prostate cancer tissues and cell lines, promoting cancer progression through interaction with TET3 and activation of the FAK/PI3K/AKT signaling pathway. The findings highlight a potential molecular mechanism contributing to advanced prostate cancer stages.

Originally published by gnews